Tandem Diabetes Care (TNDM) Revenue (2013 - 2026)

Tandem Diabetes Care has reported Revenue for 14 years, with the latest figure at $247.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 5.46% year-over-year to $247.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 4.54% YoY), and the FY2025 full-year result was $1.0 billion, up 7.93% from the prior year.
• Revenue for Q1 2026 stood at $247.2 million, down from $290.4 million in the prior quarter.
• The five-year high for Revenue was $290.4 million in Q4 2025, with the low at $169.4 million in Q1 2023.
• Historically, Revenue has averaged $220.7 million across 5 years, with a median of $220.5 million in 2022.
• Annual changes were most pronounced in 2023 — Revenue declined 10.75% — and 2024, when it soared 43.62%.
• Tandem Diabetes Care's Revenue stood at $220.5 million in 2022, then slipped by 10.75% to $196.8 million in 2023, then jumped by 43.62% to $282.6 million in 2024, then grew by 2.74% to $290.4 million in 2025, then retreated by 14.86% to $247.2 million in 2026.
• The last three Revenue figures came in at $247.2 million (Q1 2026), $290.4 million (Q4 2025), and $249.3 million (Q3 2025), per Business Quant data.